NCT00048880View on ClinicalTrials.gov

Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 5, 2002

Primary Completion Date

July 2, 2008

Study Completion Date

July 2, 2008

Conditions
Neoplasms
Interventions
DRUG

HeFi-1 Monoclonal Antibody

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00048880 - Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein | Biotech Hunter | Biotech Hunter